[Treatment of peritoneal metastases from colorectal cancer]

Ugeskr Laeger. 2022 Aug 1;184(31):V09210707.
[Article in Danish]

Abstract

Ten per cent of patients with colorectal cancer will develop peritoneal metastases. These metastases are known to have a lesser response to systemic chemotherapy than liver- and lung metastases. Randomized studies have shown that adding cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) to this treatment gives a better chance of survival. Recently, a randomized study failed to show a difference in survival between cytoreductive surgery plus HIPEC versus cytoreductive surgery alone. These facts are summarized in this review.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Colorectal Neoplasms* / pathology
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures
  • Humans
  • Hyperthermia, Induced*
  • Peritoneal Neoplasms* / drug therapy